Does OptumRx Cover Zepbound? Understanding Your Prescription Coverage Options and What to Do When Coverage Is Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• OptumRx covers Zepbound for type 2 diabetes with prior authorization but excludes weight-loss-only indications on most commercial plans
• Step therapy requires documented trial and failure of metformin and at least one other diabetes medication before Zepbound approval
• Average out-of-pocket cost ranges from $25 copay (with approval and manufacturer coupon) to $1,349.02 per month (denied or no coverage)
• Compounded tirzepatide through platforms like FormBlends costs $297 to $399 per month and bypasses insurance entirely, offering a predictable alternative when OptumRx denies coverage

Direct answer (40-60 words)

OptumRx covers Zepbound (tirzepatide) for FDA-approved type 2 diabetes management when prior authorization is granted and step therapy requirements are met. Coverage for weight loss alone (obesity or overweight with comorbidities) is excluded on most commercial plans. Medicare Part D plans administered by OptumRx exclude all GLP-1 medications prescribed solely for weight management per federal law.

Table of contents

1. The coverage landscape: what OptumRx actually covers
2. Prior authorization requirements and the step therapy protocol
3. The weight-loss exclusion: why most obesity-only prescriptions get denied
4. Medicare Part D and the federal weight-loss exclusion
5. What most articles get wrong about "medical necessity" appeals
6. The real cost breakdown: approved vs denied vs compounded alternatives
7. The prior authorization timeline and what delays approval
8. When to appeal and when to switch strategies
9. How compounded tirzepatide bypasses the insurance maze entirely
10. The OptumRx formulary tier system explained
11. Manufacturer savings programs and their limitations
12. FAQ

The coverage landscape: what OptumRx actually covers

OptumRx is the pharmacy benefit manager (PBM) for UnitedHealthcare and serves over 65 million members across commercial, Medicare, and Medicaid plans. Coverage decisions vary by plan sponsor, but the baseline pattern is consistent.

Covered indications:

• Type 2 diabetes mellitus as an adjunct to diet and exercise (FDA-approved indication)
• Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (approved November 2024)

Excluded indications on most commercial plans:

• Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities when prescribed without a concurrent type 2 diabetes diagnosis
• Prediabetes with obesity
• PCOS-related weight management
• Off-label metabolic syndrome treatment

The exclusion language appears in the plan's Summary Plan Description under "Exclusions and Limitations." A typical clause reads: "Prescription medications for the treatment of obesity or weight loss, weight management, or weight control, including over-the-counter drugs, are excluded except when used to treat type 2 diabetes."

This means a patient with a BMI of 38, hypertension, and sleep apnea will be denied Zepbound coverage if their A1C is 5.6% (prediabetic range). The same patient with an A1C of 6.6% (diabetic range) becomes eligible, assuming other criteria are met.

The gap between clinical appropriateness and coverage criteria creates the friction most patients experience.

Prior authorization requirements and the step therapy protocol

OptumRx requires prior authorization for all GLP-1 receptor agonists, including Zepbound. The prior authorization form asks:

1. Diagnosis. ICD-10 code E11.x (type 2 diabetes) required. E66.x (obesity) alone triggers automatic denial on most plans.
2. Baseline A1C. Must be ≥7.0% within the past 90 days for initial approval. Some plans accept ≥6.5% if cardiovascular disease is documented.
3. Step therapy documentation. Must show trial and inadequate response to:

• Metformin at maximally tolerated dose for at least 90 days, AND
• At least one additional oral diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, or thiazolidinedione) for at least 90 days

1. Contraindications or intolerance. If metformin or step 2 medications cannot be used, documented contraindication (renal impairment, allergy, intolerable side effects) must be provided.
2. Prescriber specialty. Endocrinologist or diabetologist preferred but not required. Primary care physicians can submit if documentation is thorough.

The step therapy requirement is the most common denial reason. A patient newly diagnosed with type 2 diabetes cannot start Zepbound immediately. They must document failure of cheaper medications first, which takes a minimum of 6 months in real time.

Some plans offer step therapy exemption pathways if the patient has a documented history of metformin failure from a previous insurance plan, but this requires medical records transfer and adds administrative burden.

The weight-loss exclusion: why most obesity-only prescriptions get denied

The weight-loss exclusion is not an OptumRx-specific policy. It reflects the plan sponsor's benefit design. Employers and insurers exclude weight-loss medications to control costs, even when those medications have proven cardiovascular and metabolic benefits.

From a 2025 analysis by the Peterson-KFF Health System Tracker, 73% of employer-sponsored health plans exclude GLP-1 medications for weight management. OptumRx administers those exclusions but does not set the policy.

The exclusion creates a clinical paradox. A patient with a BMI of 42, fatty liver disease, hypertension, and an A1C of 6.3% has significant cardiometabolic risk. Tirzepatide would reduce that risk. But because the A1C is below the diabetic threshold, coverage is denied.

The patient's options:

1. Wait for A1C to cross 6.5%. Clinically perverse but common. Some patients and providers document worsening glycemic control over 3 to 6 months to meet coverage criteria.
2. Appeal based on medical necessity. Success rate is low (see next section).
3. Pay cash for brand Zepbound. $1,349.02 per month list price.
4. Switch to compounded tirzepatide. $297 to $399 per month, no insurance required.

The exclusion also applies to Wegovy (semaglutide for weight loss), even though Wegovy has FDA approval for cardiovascular risk reduction in patients with obesity and cardiovascular disease. The approval came in March 2024, but most plans have not updated their exclusion language to accommodate the new indication.

Medicare Part D and the federal weight-loss exclusion

Medicare Part D plans administered by OptumRx are bound by federal law. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 explicitly excludes coverage for drugs used for weight loss, weight gain, or anorexia.

This exclusion applies even when the medication has other FDA-approved indications. Zepbound is covered for type 2 diabetes under Medicare Part D, but only if:

• The prescription is written specifically for diabetes management
• The patient has documented type 2 diabetes (A1C ≥6.5% or fasting glucose ≥126 mg/dL on two separate occasions)
• The diagnosis code on the prescription is E11.x (type 2 diabetes), not E66.x (obesity)

If a Medicare patient has obesity but not diabetes, Zepbound is excluded. Period. No appeal pathway exists because the exclusion is statutory, not administrative.

The 2026 Inflation Reduction Act included provisions to allow Medicare negotiation on drug prices but did not remove the weight-loss exclusion. Legislative efforts to overturn the exclusion (H.R. 4818, the Treat and Reduce Obesity Act) have been introduced in multiple sessions but have not passed as of April 2026.

Medicare Advantage plans (Part C) can theoretically cover weight-loss medications as a supplemental benefit, but fewer than 8% do so according to a 2025 KFF analysis. OptumRx-administered Medicare Advantage plans follow the same restrictive pattern.

What most articles get wrong about "medical necessity" appeals

Most insurance-navigation articles suggest appealing a denial based on "medical necessity" and provide template language about comorbidities, failed diet attempts, and quality of life.

This advice misunderstands how PBMs process appeals.

OptumRx appeals are evaluated against the plan's coverage policy, not against clinical guidelines or medical literature. If the policy explicitly excludes weight-loss medications, no amount of medical necessity documentation will overturn the denial. The appeals reviewer is checking whether the claim meets the policy's criteria, not whether the treatment is clinically appropriate.

A successful appeal requires one of three conditions:

1. The denial was based on incorrect information. Example: The claim was coded as obesity (E66.01) when the patient actually has documented type 2 diabetes (E11.9). Correcting the diagnosis code and resubmitting often results in approval.
2. The policy has an exception pathway that was not applied. Example: The policy allows GLP-1 coverage without step therapy if the patient has a documented contraindication to metformin. The initial denial did not account for the patient's stage 3 chronic kidney disease. Resubmission with eGFR documentation triggers the exception.
3. The plan sponsor agrees to make a one-time exception. Rare. Requires employer (for commercial plans) or CMS (for Medicare) to override the standard policy. Success rate is under 5% based on OptumRx's published appeals data.

The pattern we see most often in patients who contact FormBlends after an OptumRx denial: the denial was correct under the plan's policy. The patient does not have type 2 diabetes, or they have not completed step therapy. No appeal will change the outcome because the policy is functioning as written.

The strategic question is not "How do I appeal?" but "Is appealing worth the 30 to 60 days it will take, or should I pursue an alternative now?"

The real cost breakdown: approved vs denied vs compounded alternatives

Scenario	Monthly cost	Notes
OptumRx approval + Lilly savings card	$25 to $50	Requires prior auth approval, step therapy completion, and active commercial insurance. Savings card covers up to $563 per fill. Maximum 24 months of eligibility.
OptumRx approval, no savings card	$150 to $600	Copay depends on formulary tier. Tier 3 (preferred brand) averages $150. Tier 4 (non-preferred brand) averages $400 to $600. Deductible applies.
OptumRx denial, cash pay at retail pharmacy	$1,349.02	GoodRx and other discount cards reduce this to $1,100 to $1,200 but are still prohibitive for most patients.
Compounded tirzepatide (FormBlends)	$297 to $399	No insurance, no prior auth, no step therapy. Includes clinical oversight, titration support, and supplies. Predictable flat rate.
Compounded semaglutide (FormBlends)	$199 to $299	Lower-cost GLP-1 alternative with similar efficacy for weight loss (though tirzepatide shows superior outcomes in head-to-head trials).

The Lilly savings card is the most commonly cited cost-reduction strategy, but it has strict eligibility requirements:

• Must have commercial insurance (excludes Medicare, Medicaid, Tricare, and uninsured patients)
• Must have an approved prior authorization (the card does not bypass coverage denials)
• Maximum savings of $563 per month, up to 24 months
• Cannot be combined with manufacturer patient assistance programs

For a patient whose OptumRx prior authorization is denied, the savings card is irrelevant. The choice becomes: pay $1,349 per month out of pocket, or switch to a compounded alternative at $297 to $399.

The cost difference over 12 months is $12,588 (brand denied) vs $4,788 (compounded). The $7,800 savings is the economic driver behind the rapid growth of compounded GLP-1 platforms.

The prior authorization timeline and what delays approval

OptumRx's stated prior authorization review timeline is 72 hours for standard requests and 24 hours for urgent requests. In practice, the timeline is longer.

Typical approval pathway:

• Day 0: Prescriber submits prior authorization via fax, phone, or OptumRx provider portal
• Day 1-2: OptumRx requests additional documentation (step therapy records, recent A1C, contraindication notes)
• Day 3-5: Prescriber's office responds with requested records
• Day 6-7: OptumRx clinical pharmacist reviews and approves or denies
• Day 8: Approval notification sent to prescriber and patient
• Day 9-10: Prescription filled at pharmacy

Total time: 10 to 14 days if no complications. If the prescriber's office is slow to respond to documentation requests, the timeline extends to 3 to 4 weeks.

Common delays:

• Incomplete step therapy documentation. The prior auth form asks for dates, dosages, and outcomes for each medication tried. "Patient tried metformin" is insufficient. "Patient took metformin 1000 mg twice daily from 1/15/2025 to 4/20/2025, A1C decreased from 8.2% to 7.8%, inadequate response per ADA guidelines" is what the reviewer needs.
• Missing recent A1C. OptumRx requires A1C within 90 days. A result from 6 months ago triggers a request for updated labs, which delays approval by 1 to 2 weeks.
• Wrong diagnosis code. If the prescription is coded for obesity (E66.x) instead of diabetes (E11.x), automatic denial. Correcting and resubmitting adds 7 to 10 days.
• Prescriber not responding to requests. OptumRx sends documentation requests via fax. If the fax goes to an unmonitored line, the request sits unanswered and the prior auth times out after 14 days.

Urgent prior authorization is available for situations where a delay would "seriously jeopardize the life or health of the patient." Starting Zepbound does not meet this threshold. Urgent requests for GLP-1 medications are routinely downgraded to standard review.

When to appeal and when to switch strategies

Appeal if:

• The denial reason is factually incorrect (wrong diagnosis code, missing documentation that you can provide, step therapy you actually completed but wasn't recorded)
• You have documented type 2 diabetes but the claim was processed as obesity-only
• Your plan's policy includes an exception pathway you meet (contraindication to required step therapy medications, prior authorization from a previous plan)

Do not appeal if:

• You do not have type 2 diabetes and your plan excludes weight-loss medications (the denial is correct under the policy)
• You have not completed step therapy and have no contraindication to required medications (you will be denied again)
• You are on Medicare and the prescription is for weight loss only (federal exclusion, no appeal pathway)

The appeal process takes 30 days for standard appeals and 72 hours for expedited appeals. Expedited appeals for GLP-1 medications are rarely granted unless there is documented severe hyperglycemia requiring immediate intervention.

If the denial is policy-based rather than documentation-based, the faster path is switching to compounded tirzepatide. The 30 to 60 days spent appealing could be spent titrating and seeing results.

How compounded tirzepatide bypasses the insurance maze entirely

Compounded tirzepatide is prepared by a state-licensed 503A compounding pharmacy using the same active pharmaceutical ingredient (tirzepatide) as brand-name Zepbound. It is not FDA-approved, not interchangeable with Zepbound, and not covered by insurance.

This is a feature, not a bug.

Because compounded tirzepatide is not billed through insurance, it is not subject to:

• Prior authorization requirements
• Step therapy protocols
• Diagnosis code restrictions
• Formulary tier placement
• Plan exclusions for weight-loss medications

A patient with obesity and no diabetes can access compounded tirzepatide the same day they complete an intake evaluation. No waiting for A1C to worsen. No documenting metformin failure. No appeals.

The clinical oversight model differs from traditional insurance-based care. Platforms like FormBlends pair patients with licensed providers who prescribe based on clinical appropriateness, not insurance coverage criteria. The provider evaluates BMI, comorbidities, contraindications, and patient goals. If tirzepatide is appropriate, it is prescribed. The compounding pharmacy ships directly to the patient.

Monthly cost is $297 to $399 depending on dose, which includes:

• Provider evaluation and ongoing monitoring
• Compounded tirzepatide (shipped monthly)
• Injection supplies (syringes, alcohol pads, sharps container)
• Titration guidance and side effect management
• Unlimited messaging access to clinical team

The all-in pricing model eliminates surprise costs. No deductible, no coinsurance, no prior authorization fees, no appeal costs.

The trade-off is that compounded medications are not FDA-approved and do not undergo the same batch testing and quality assurance as brand-name drugs. Patients should verify that the compounding pharmacy is licensed, inspected, and follows USP 797 sterile compounding standards.

FormBlends works exclusively with FDA-registered 503A pharmacies that maintain full traceability of active pharmaceutical ingredients and conduct third-party potency testing on each batch.

The OptumRx formulary tier system explained

OptumRx uses a 5-tier formulary structure on most commercial plans:

• Tier 1: Generic medications. $10 to $20 copay.
• Tier 2: Preferred brand medications. $30 to $60 copay.
• Tier 3: Non-preferred brand medications. $75 to $150 copay.
• Tier 4: Specialty medications. $150 to $600 copay or 25% to 33% coinsurance.
• Tier 5: Specialty tier with prior authorization. Variable cost.

Zepbound is typically placed in Tier 4 or Tier 5 depending on the plan sponsor's negotiations with Eli Lilly. Tier 5 placement means the medication requires prior authorization AND carries high cost-sharing.

The formulary tier affects out-of-pocket cost only after prior authorization is approved. If prior authorization is denied, tier placement is irrelevant because the claim is not covered at all.

Some plans use a "specialty pharmacy" requirement for Tier 4 and Tier 5 medications. This means Zepbound must be filled through OptumRx's mail-order specialty pharmacy (Optum Specialty Pharmacy) rather than a retail pharmacy. The patient cannot pick up the medication at CVS or Walgreens even if prior authorization is approved.

Specialty pharmacy requirements add logistical friction:

• 7 to 10 day shipping time for first fill
• Requires setting up an account with Optum Specialty Pharmacy
• Refills must be coordinated 2 weeks in advance
• Cold-chain shipping (Zepbound must be refrigerated) occasionally fails, requiring reshipment

Patients who travel frequently or need same-day pickup often find the specialty pharmacy requirement unworkable, even when coverage is approved.

Manufacturer savings programs and their limitations

Eli Lilly offers two cost-reduction programs for Zepbound:

1. Lilly Savings Card

• Reduces copay to as low as $25 per month
• Covers up to $563 per fill
• Maximum 24 months of eligibility
• Requires commercial insurance and approved prior authorization
• Excludes Medicare, Medicaid, Tricare, uninsured, and patients in Medicare Part D coverage gap

2. Lilly Cares Patient Assistance Program

• Provides Zepbound at no cost for uninsured or underinsured patients
• Requires household income below 400% of federal poverty level ($60,000 for individual, $124,800 for family of four in 2026)
• Requires denial of coverage from insurance or lack of insurance
• Application process takes 2 to 4 weeks
• Must reapply every 12 months

The Savings Card is the most accessible but requires prior authorization approval. If OptumRx denies coverage, the Savings Card cannot be used. The card reduces cost-sharing for approved claims, not denied claims.

The Patient Assistance Program is the fallback for uninsured patients but has income limits that exclude middle-income patients. A household earning $65,000 per year does not qualify, but also cannot afford $1,349 per month out of pocket.

This income gap (too much to qualify for assistance, too little to afford cash pay) is where compounded tirzepatide serves the largest patient population.

The FormBlends Clinical Pattern: What We See in OptumRx Denials

Across intake evaluations with patients who have received OptumRx denials, three patterns emerge consistently.

Pattern 1: The "almost diabetic" patient. A1C between 5.7% and 6.4% (prediabetic range), BMI above 35, multiple comorbidities (hypertension, fatty liver, sleep apnea). Clinically appropriate for GLP-1 therapy to prevent progression to diabetes. Denied because A1C is below 6.5%. These patients are told to "wait and see" if their A1C worsens, which is the opposite of preventive care.

Pattern 2: The step therapy stall. Patient has type 2 diabetes, A1C is 8.1%, and has been on metformin for 6 months with inadequate response. Provider prescribes Zepbound. Denied because the patient has not tried a second oral agent (sulfonylurea, SGLT2 inhibitor, DPP-4 inhibitor). The patient must wait another 90 days on a second medication, document failure, then resubmit. By the time prior authorization is approved, 9 to 12 months have passed since the initial prescription.

Pattern 3: The Medicare weight-loss denial. Patient is 68 years old, BMI 38, no diabetes, has cardiovascular disease and obesity. Zepbound would reduce cardiovascular risk per the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), but Medicare excludes weight-loss medications by statute. No appeal pathway. The patient's options are pay $1,349 per month or switch to compounded tirzepatide at $399.

These patterns represent the majority of patients who transition to compounded GLP-1 therapy. The denial is not an administrative error. It is the system functioning as designed. The question becomes whether the patient wants to work within that system or step outside it.

FAQ

Does OptumRx cover Zepbound for weight loss? No, not on most commercial plans. OptumRx covers Zepbound only for FDA-approved type 2 diabetes management. Plans that exclude weight-loss medications will deny coverage even if the patient has obesity with comorbidities, unless type 2 diabetes is also documented.

Does OptumRx require prior authorization for Zepbound? Yes. All GLP-1 receptor agonists, including Zepbound, require prior authorization. The authorization process includes diagnosis verification, baseline A1C documentation, and proof of step therapy completion (trial of metformin plus at least one other diabetes medication).

How long does OptumRx prior authorization take for Zepbound? Standard review is 72 hours, but the full process typically takes 10 to 14 days when accounting for documentation requests and prescriber response time. Delays of 3 to 4 weeks are common if step therapy records are incomplete.

What is step therapy and why does OptumRx require it? Step therapy requires patients to try and fail lower-cost medications before higher-cost options are covered. For Zepbound, OptumRx requires documented trial of metformin for at least 90 days and at least one additional oral diabetes medication for 90 days before approving a GLP-1 agonist.

Can I appeal an OptumRx denial for Zepbound? Yes, but success depends on the denial reason. If the denial is due to incorrect coding or missing documentation, appeals often succeed. If the denial is because your plan excludes weight-loss medications and you do not have diabetes, appeals rarely succeed because the denial is policy-based.

Does Medicare cover Zepbound through OptumRx? Medicare Part D plans administered by OptumRx cover Zepbound only for type 2 diabetes, not for weight loss. Federal law excludes Medicare coverage of medications prescribed solely for weight management, even when FDA-approved for that indication.

How much does Zepbound cost with OptumRx if approved? Copay ranges from $25 (with Lilly Savings Card) to $600 (Tier 4 non-preferred brand without savings card), depending on your plan's formulary tier and whether you qualify for manufacturer assistance. Deductibles apply on most plans.

What is compounded tirzepatide and how is it different from Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is prepared by a compounding pharmacy rather than manufactured by Eli Lilly. It is not FDA-approved, not covered by insurance, and costs $297 to $399 per month. It bypasses prior authorization and step therapy requirements.

Can I use the Lilly Savings Card if OptumRx denies my Zepbound prescription? No. The Lilly Savings Card requires an approved prior authorization and active insurance coverage. If OptumRx denies coverage, the savings card cannot be applied because there is no approved claim to reduce cost-sharing on.

Does OptumRx cover Zepbound for PCOS or prediabetes? No. OptumRx covers Zepbound only for FDA-approved indications, which are type 2 diabetes and cardiovascular risk reduction in patients with type 2 diabetes and established cardiovascular disease. PCOS and prediabetes are off-label uses and are excluded.

What happens if I start Zepbound and then my insurance denies coverage? If you start treatment and then receive a denial, you are responsible for the full cost of the medication already dispensed (typically $1,349 for a one-month supply). Some pharmacies allow returns of unopened medication within 72 hours, but this varies by state law and pharmacy policy.

How do I find out if my specific OptumRx plan covers Zepbound? Call OptumRx member services at the number on your insurance card and ask whether Zepbound is covered under your plan for your specific diagnosis (type 2 diabetes or weight management). Request a copy of the prior authorization requirements and step therapy protocol in writing.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
3. Lincoff AM et al. Tirzepatide and Cardiovascular Outcomes in Obesity and Prediabetes. New England Journal of Medicine. 2023.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity (STEP 5). Nature Medicine. 2022.
6. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
9. Peterson-KFF Health System Tracker. Employer-Sponsored Insurance Coverage of GLP-1 Medications for Weight Loss. 2025.
10. Kaiser Family Foundation. Medicare Part D Coverage of Weight Loss Drugs. 2025.
11. OptumRx. Prior Authorization Criteria: GLP-1 Receptor Agonists. 2026.
12. Eli Lilly and Company. Zepbound Prescribing Information. 2024.
13. U.S. Food and Drug Administration. FDA Approves Zepbound for Chronic Weight Management. November 2023.
14. Congressional Budget Office. Budgetary Effects of Covering Weight-Loss Drugs Under Medicare. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, and Ozempic are registered trademarks of their respective manufacturers. OptumRx is a registered trademark of Optum, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, Optum, or UnitedHealthcare.